1.	Studerus, E., Gamma, A. & Vollenweider, F. X. Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV). PLOS ONE 5, e12412 (2010).
2.	Kraehenmann, R. et al. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biological Psychiatry 78, 572–581 (2015).
3.	Barrett, F. S., Carbonaro, T. M., Hurwitz, E., Johnson, M. W. & Griffiths, R. R. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. Psychopharmacology (Berl) 235, 2915–2927 (2018).
4.	Doss, M. K. et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry 11, 1–10 (2021).
5.	Yaden, D. B., Goldy, S. P., Weiss, B. & Griffiths, R. R. Clinically relevant acute subjective effects of psychedelics beyond mystical experience. Nat Rev Psychol 3, 606–621 (2024).
6.	Chen, J. et al. Shared memories reveal shared structure in neural activity across individuals. Nat Neurosci 20, 115–125 (2017).
7.	Lerner, Y., Honey, C. J., Silbert, L. J. & Hasson, U. Topographic Mapping of a Hierarchy of Temporal Receptive Windows Using a Narrated Story. J. Neurosci. 31, 2906–2915 (2011).
8.	Simony, E. et al. Dynamic reconfiguration of the default mode network during narrative comprehension. Nat Commun 7, 12141 (2016).

